BioCentury | Oct 28, 2020
Distillery Therapeutics

Inhibiting IL-33-driven inflammation to treat brain cancer

...for atopic dermatitis, severe asthma and chronic rhinosinusitis with nasal polyps.Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi...
BioCentury | Oct 22, 2020
Product Development

Data Byte: AbbVie’s oral JAK takes the lead in coming competition for Dupixent in atopic dermatitis

...the market leader Dupixent, an IL-4R and IL-13 inhibitor from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi...
...Other) Dupixent (Brand), SAR231893 (Compound #), REGN668 (Compound #), dupilumab (Generic), Dupixent (Informal) tralokinumab (CAT-354) AbbVie Inc. Regeneron Pharmaceuticals Inc. Sanofi Dermatology Dermatitis...
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...play Innovent Biologics Inc. (HKEX:1801) hired Yong Jun Liu president. Liu was global head of research at Sanofi...
BioCentury | Oct 16, 2020
Product Development

WHO data show quartet of therapies fail to reduce COVID death

...reduce 28-day mortality in hospitalized COVID-19 patients, missing the primary endpoint.The data came as Sinopharm and partners Sanofi...
...Global Times reported that China has been offering citizens a COVID-19 vaccine from Sinopharm since July 22.Separately, Sanofi...
...and led to Th1-biased T cell responses in both animals.TARGETSIFNB1 – Interferon β Sandi Wong BBIBP-CorV Veklury, remdesivir (GS-5734) Sanofi Translate...
BioCentury | Oct 14, 2020
Management Tracks

Ex-Sanofi CMO Nathwani to lead Dewpoint; plus Inozyme, ReCode and Frazier

...and a member of the board of directors. Nathwani joins the biomolecular condensates company from Sanofi...
...than two decades, Nathwani has led the development of more than 20 drugs and, at Sanofi...
...is retiring. Sabbagh was previously the head of rare renal and musculoskeletal diseases research at Sanofi...
BioCentury | Oct 9, 2020
Product Development

COVID-19 Quick Takes: Moderna won’t challenge vaccine IP, wins contract for mobile GMP manufacturing

...COVID-19 vaccines following deals with AstraZeneca plc (LSE:AZN; NYSE:AZN) and the University of Oxford, and Sanofi...
BioCentury | Oct 6, 2020
Management Tracks

BioMarin, Sanofi tap new execs for early R&D positions

...to head of research, CSO; Eggan joins BioMarin By Paul Bonanos, Associate Editor BioMarin and Sanofi...
...and EnClear Therapies Inc. and QurAlis Corp., each of which has programs to treat amyotrophic lateral sclerosis.Sanofi...
...of R&D John Reed.Spokesperson Ashleigh Koss told BioCentury that both of Nestle’s predecessors have left Sanofi...
BioCentury | Oct 6, 2020
Product Development

Warp Speed asking biopharmas to delay seeking EUA until they have enough doses

...being made by Novavax Inc. (NASDAQ:NVAX) and Sanofi...
BioCentury | Oct 1, 2020
Politics, Policy & Law

Revlimid, Copaxone are poster children for price abuses, House committee says

...Sarclisa isatuximab-irfc, a multiple myeloma drug from Sanofi...
...NASDAQ:SNY), would be available at year-end. Because Sanofi...
...combination of Sarclisa and Revlimid and help Sanofi...
BioCentury | Sep 26, 2020
Politics, Policy & Law

Warp Speed’s Slaoui expects two COVID-19 vaccines this year, rebuts Sen. Warren

...Sept. 21.In the absence of Warp Speed, Sanofi...
...[from Operation Warp Speed]. It's not true. Sanofi...
...yet have started its Phase I trial. The Sanofi...
Items per page:
1 - 10 of 6669
BioCentury | Oct 28, 2020
Distillery Therapeutics

Inhibiting IL-33-driven inflammation to treat brain cancer

...for atopic dermatitis, severe asthma and chronic rhinosinusitis with nasal polyps.Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi...
BioCentury | Oct 22, 2020
Product Development

Data Byte: AbbVie’s oral JAK takes the lead in coming competition for Dupixent in atopic dermatitis

...the market leader Dupixent, an IL-4R and IL-13 inhibitor from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi...
...Other) Dupixent (Brand), SAR231893 (Compound #), REGN668 (Compound #), dupilumab (Generic), Dupixent (Informal) tralokinumab (CAT-354) AbbVie Inc. Regeneron Pharmaceuticals Inc. Sanofi Dermatology Dermatitis...
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...play Innovent Biologics Inc. (HKEX:1801) hired Yong Jun Liu president. Liu was global head of research at Sanofi...
BioCentury | Oct 16, 2020
Product Development

WHO data show quartet of therapies fail to reduce COVID death

...reduce 28-day mortality in hospitalized COVID-19 patients, missing the primary endpoint.The data came as Sinopharm and partners Sanofi...
...Global Times reported that China has been offering citizens a COVID-19 vaccine from Sinopharm since July 22.Separately, Sanofi...
...and led to Th1-biased T cell responses in both animals.TARGETSIFNB1 – Interferon β Sandi Wong BBIBP-CorV Veklury, remdesivir (GS-5734) Sanofi Translate...
BioCentury | Oct 14, 2020
Management Tracks

Ex-Sanofi CMO Nathwani to lead Dewpoint; plus Inozyme, ReCode and Frazier

...and a member of the board of directors. Nathwani joins the biomolecular condensates company from Sanofi...
...than two decades, Nathwani has led the development of more than 20 drugs and, at Sanofi...
...is retiring. Sabbagh was previously the head of rare renal and musculoskeletal diseases research at Sanofi...
BioCentury | Oct 9, 2020
Product Development

COVID-19 Quick Takes: Moderna won’t challenge vaccine IP, wins contract for mobile GMP manufacturing

...COVID-19 vaccines following deals with AstraZeneca plc (LSE:AZN; NYSE:AZN) and the University of Oxford, and Sanofi...
BioCentury | Oct 6, 2020
Management Tracks

BioMarin, Sanofi tap new execs for early R&D positions

...to head of research, CSO; Eggan joins BioMarin By Paul Bonanos, Associate Editor BioMarin and Sanofi...
...and EnClear Therapies Inc. and QurAlis Corp., each of which has programs to treat amyotrophic lateral sclerosis.Sanofi...
...of R&D John Reed.Spokesperson Ashleigh Koss told BioCentury that both of Nestle’s predecessors have left Sanofi...
BioCentury | Oct 6, 2020
Product Development

Warp Speed asking biopharmas to delay seeking EUA until they have enough doses

...being made by Novavax Inc. (NASDAQ:NVAX) and Sanofi...
BioCentury | Oct 1, 2020
Politics, Policy & Law

Revlimid, Copaxone are poster children for price abuses, House committee says

...Sarclisa isatuximab-irfc, a multiple myeloma drug from Sanofi...
...NASDAQ:SNY), would be available at year-end. Because Sanofi...
...combination of Sarclisa and Revlimid and help Sanofi...
BioCentury | Sep 26, 2020
Politics, Policy & Law

Warp Speed’s Slaoui expects two COVID-19 vaccines this year, rebuts Sen. Warren

...Sept. 21.In the absence of Warp Speed, Sanofi...
...[from Operation Warp Speed]. It's not true. Sanofi...
...yet have started its Phase I trial. The Sanofi...
Items per page:
1 - 10 of 6669